Background: External validation of prognostic risk models is essential before they are implemented in clinical practice. This study evaluated the recently developed MEGNA score for survival prediction after resection of intrahepatic cholangiocarcinoma (ICC), with a focus on the direct comparison of its prognostic value to that of the current International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) Cancer staging system.
Material and methods: Between 1997 and 2018, 417 consecutive patients with ICC were referred to our tertiary care centre and were retrospectively identified out of a dedicated clinical database. Of this group, 203 patients underwent surgical resection and met the inclusion criteria. Multivariate analysis was performed to assess the predictors of the recently proposed MEGNA score regarding overall survival (OS). Concordance indices (C-indices) and integrated Brier scores (IBS) were calculated to assess the ability of both the MEGNA score and the current (8th) edition of the UICC/AJCC Cancer staging system to predict individual patient outcome.
Results: Stratification according to the MEGNA score resulted in a median OS of 34.5 months, 26.1 months, 21.5 months, and 16.6 months for MEGNA scores 0, 1, 2, and ≥3, respectively (log rank p < 0.001). However, of the five factors that contribute to the MEGNA score, age > 60 years was not a predictor for poor OS in our cohort. The C-index for the MEGNA score was 0.58, the IBS was 0.193. The 8th edition of the UICC/AJCC system performed slightly better, with a C-index of 0.61 and an IBS of 0.186.
Conclusion: The ability of the MEGNA score to predict individual patient outcome was only moderate in this external validation. Its prognostic value did not reach that of the more widely known and used UICC/AJCC system. However, neither scoring system performed well enough to support clear-cut clinical decisions.
Conflict of interest statement
The authors have declared that no competing interests exist.
Survival in Papillary Thyroid Microcarcinoma: A Comparative Analysis Between the 7th and 8th Versions of the AJCC/UICC Staging System Based on the SEER Database.Front Endocrinol (Lausanne). 2019 Jan 24;10:10. doi: 10.3389/fendo.2019.00010. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 30733707 Free PMC article.
Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis.J Surg Oncol. 2017 Nov;116(6):643-650. doi: 10.1002/jso.24720. Epub 2017 Jun 12. J Surg Oncol. 2017. PMID: 28608424
Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation.Cancer Commun (Lond). 2018 Nov 19;38(1):67. doi: 10.1186/s40880-018-0337-5. Cancer Commun (Lond). 2018. PMID: 30454049 Free PMC article. Clinical Trial.
Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates.Chin Clin Oncol. 2018 Oct;7(5):52. doi: 10.21037/cco.2018.07.03. Epub 2018 Jul 12. Chin Clin Oncol. 2018. PMID: 30180751 Review.
Staging of intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr. 2017 Feb;6(1):35-43. doi: 10.21037/hbsn.2016.10.02. Hepatobiliary Surg Nutr. 2017. PMID: 28261593 Free PMC article. Review.